FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, namely to monoclonal antibody, which is capable of inhibiting dimerization of c-Met. Composition for preventing and treating cancer, associated with c-Met, containing said antibody is also disclosed. Application of said antibody and composition is disclosed for preparing therapeutic agent against cancer, associated with c-Met.
EFFECT: invention is capable of total inhibiting dimerization of c-Met, which enables effective treatment of cancer, characterized by ligand-independent c-Met activation.
19 cl, 39 dwg, 4 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| METHOD FOR MODELLING MONOCLONAL ANTIBODY ANTAGONISTIC ACTIVITY | 2009 |
|
RU2575600C2 |
| NEW ANTIBODIES INHIBITING C-MET DIMERISATION AND USING THEM | 2008 |
|
RU2552161C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
| C-MET ANTAGONIST AND AMINOHETEROARYL COMBINATION FOR TREATING CANCER | 2009 |
|
RU2526171C2 |
| ANTI-MET ANTIBODIES AND THEIR USE | 2017 |
|
RU2765267C2 |
| HUMANISED MONOCLONAL ANTIBODIES TO HEPATOCYTE GROWTH FACTOR | 2007 |
|
RU2461570C2 |
| CONJUGATES OF CMET ANTIBODY AND DRUG AND METHODS OF USING | 2017 |
|
RU2740996C2 |
| NOVEL ANTIBODY FOR DIAGNOSIS AND/OR PROGNOSIS OF CANCER | 2011 |
|
RU2651513C2 |
| ANTI-cMet ANTIBODY AND USE THEREOF FOR DETECTION AND DIAGNOSIS OF CANCER | 2010 |
|
RU2582265C2 |
